Serotonin type 3 receptor (5-HT 3 R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.
Megan R Mayer, Tse-Hwei Choo, Daniel C Javitt et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of serotonin type 3 receptor (5-HT 3 R) antagonists in treating negative symptoms and cognitive impairment associated with schizophrenia. Analyzing 12 active versus placebo comparisons involving 730 participants, the study found a moderate effect size for both negative symptoms (Cohen's d = -0.52) and cognitive impairment (Cohen's d = -0.53), indicating significant benefits from these adjunctive treatments.
Key findings
- 5-HT 3 R antagonists showed a moderate effect on negative symptoms with Cohen's d = -0.52.
- Cognitive impairment associated with schizophrenia improved with 5-HT 3 R antagonists, Cohen's d = -0.53.
- The analysis included 12 active versus placebo comparisons across 730 participants.
Why it matters
The findings suggest that 5-HT 3 R antagonists may provide additional benefits for patients with schizophrenia who experience treatment-resistant negative symptoms and cognitive impairment, highlighting the need for further research in this area.